AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.
Financial Results:
Astrazeneca Pharma India Ltd reported Revenues for Q2FY25 of ₹8,028.00 Crores down from ₹8,479.00 Crore year on year, a fall of 5.32%.
Total Expenses for Q2FY25 of ₹7,093.00 Crores up from ₹7,022.00 Crores year on year, a rise of 1.01%.
Consolidated Net Profit of ₹694.00 Crores down 43.67% from ₹1,232.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹7.24, down 42.40% from ₹12.57 in the same quarter of the previous year.